<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3335">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04476680</url>
  </required_header>
  <id_info>
    <org_study_id>1070MODREC20</org_study_id>
    <nct_id>NCT04476680</nct_id>
  </id_info>
  <brief_title>Influence of Military Preventive Policy for reCruit Training on COVID-19 Seroconversion</brief_title>
  <acronym>IMPACTCOVID</acronym>
  <official_title>Influence of Military Preventive Policy for reCruit Training on COVID-19 Seroconversion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Centre for Defence Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Leeds Beckett University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liverpool John Moores University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Royal Centre for Defence Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is intended to address the association between vitamin D status and seroconversion&#xD;
      to SARS-CoV-2 in healthy young adults.&#xD;
&#xD;
      The primary aim of the study is to determine the rates of 'silent' seroconversion rates,&#xD;
      consistent with asymptomatic transmission of SARS-CoV-2, in a young healthy adult population&#xD;
      with a wide spread of vitamin D concentrations.&#xD;
&#xD;
      The secondary aims of this study are to explore:&#xD;
&#xD;
        1. Any effect of vitamin D status on symptomatic illness.&#xD;
&#xD;
        2. The background 'point' prevalence and subsequent rate of increase in seropositivity for&#xD;
           SARS-CoV-2 in healthy young adults.&#xD;
&#xD;
        3. The individual reductions in seropositivity to SARS-CoV-2 over time, and changes in&#xD;
           seropositivity in a defined young adult population over time.&#xD;
&#xD;
        4. Where salivary Immunoglobulin A (IgA) may be used to provide an alternative/&#xD;
           complementary serological method&#xD;
&#xD;
        5. The effect (if any) of vitamin D supplementation on seroconversion rates stratified by:&#xD;
           i) level of baseline vitamin D 'deficiency/ insufficiency/ sufficiency' status; ii)&#xD;
           extent of BMI-defined normal/overweight/obesity cut-offs and iii) gender.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary aim of the study is to determine the rates of 'silent' seroconversion rates,&#xD;
      consistent with asymptomatic transmission of SARS-CoV-2, in a young healthy adult population&#xD;
      with a wide spread of vitamin D concentrations.&#xD;
&#xD;
      The study will be conducted over 16 weeks in two populations: Service Personnel undertaking&#xD;
      initial military training, who are supplementing with vitamin D (1000 IU/day D3 for 4 weeks,&#xD;
      and 400 IU/d D3 as a maintenance dose), and civilian students who are not supplementing.&#xD;
&#xD;
      We will recruit adults aged 18-30 years old. Military and civilian participants will be&#xD;
      recruited respectively in Catterick and Leeds, UK to start in coincidence with the&#xD;
      recommencement of Autumn semester.&#xD;
&#xD;
      In accordance with our power calculation and anticipated drop-out rate, 450 volunteers will&#xD;
      be recruited in each group. Data collected at baseline and after 5, 9, 12 and 16 weeks will&#xD;
      include seroconversion status assessed from a validated Dried Blood Spot (DBS) method in&#xD;
      conjunction with novel salivary antibody testing, plus structured questionnaire responses&#xD;
      screening for Covid-19 symptoms. Physical and demographic characteristics and serum levels of&#xD;
      vitamin D concentrations collected from participants at study entry will facilitate secondary&#xD;
      aims in relation to exploring the influence of gender, ethnicity, body mass and body mass&#xD;
      index (BMI) on asymptomatic seroconversion, as well as interactions with vitamin D status and&#xD;
      supplementation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">April 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 28, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Observational study in two cohorts, matched for age and latitude. One group will be taking vitamin D supplements.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seroconversion</measure>
    <time_frame>24 weeks</time_frame>
    <description>asymptomatic seroconversion for SARS-CoV-2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interim analysis - seropositivity at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>asymptomatic seroconversion for SARS-CoV-2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dried Blood Spot performance</measure>
    <time_frame>24 weeks</time_frame>
    <description>Sensitivity and specificity of dried blood spot assay compared with venous blood serology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Salivary IgA performance</measure>
    <time_frame>24 weeks</time_frame>
    <description>Sensitivity and specificity of salivary IgA compared with venous blood serology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of SARS-CoV-2</measure>
    <time_frame>24 weeks</time_frame>
    <description>The background 'point' prevalence and subsequent rate of increase in seropositivity for SARS-CoV-2 in healthy young adults.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in seropositivity</measure>
    <time_frame>24 weeks</time_frame>
    <description>The individual reductions in seropositivity to SARS-CoV-2 over time, and changes in seropositivity in a defined young adult population over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in seroconversion rate</measure>
    <time_frame>24 weeks</time_frame>
    <description>The effect of vitamin D supplementation on seroconversion rates stratified by: i) level of baseline vitamin D 'deficiency/ insufficiency/ sufficiency' statusÍ¾ ii) extent of BMI-defined normal/overweight/obesity cut-offs, iii) gender iv) ethnicity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">900</enrollment>
  <condition>SARS-CoV Infection</condition>
  <condition>Vitamin D Deficiency</condition>
  <condition>Covid19</condition>
  <condition>Acute Respiratory Tract Infection</condition>
  <arm_group>
    <arm_group_label>Military recruits</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitamin D supplementation (1000 IU/day D3 for 4 weeks, and 400 IU/d D3 as a maintenance dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>Pure Encapsulations' manufacturing facility is a US Food and Drug Administration (FDA) inspected and NSF International Good Manufacturing Practices registered company.</description>
    <arm_group_label>Military recruits</arm_group_label>
    <other_name>Pure Encapsulations, Sudbury, MA, USA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able to access the study sites at Leeds Beckett University's Headingley or City&#xD;
             campuses, UK OR recruit at Infantry Training Centre, Catterick Garrison, UK&#xD;
&#xD;
          -  In possession of an internet-enabled smart phone capable of receiving and responding&#xD;
             to smartphone alerts.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previously diagnosed with COVID-19 either by RT-PCR or serologically (either prior to&#xD;
             the study or at initial baseline testing).&#xD;
&#xD;
          -  Use of over-the-counter or prescribed vitamin D supplements currently or in the past&#xD;
             month&#xD;
&#xD;
          -  Condition conferring 'very high risk' or 'high risk' of severe COVID-19&#xD;
&#xD;
               -  have had an organ transplant&#xD;
&#xD;
               -  are having chemotherapy or antibody treatment for cancer, including immunotherapy&#xD;
&#xD;
               -  are having an intense course of radiotherapy (radical radiotherapy) for lung&#xD;
                  cancer&#xD;
&#xD;
               -  are having targeted cancer treatments that can affect the immune system (such as&#xD;
                  protein kinase inhibitors or PARP inhibitors)&#xD;
&#xD;
               -  have blood or bone marrow cancer (such as leukaemia, lymphoma or myeloma)&#xD;
&#xD;
               -  have had a bone marrow or stem cell transplant in the past 6 months, or are still&#xD;
                  taking immunosuppressant medicine&#xD;
&#xD;
               -  are pregnant or intent on becoming pregnant during the anticipated study period&#xD;
&#xD;
               -  have a learning disability&#xD;
&#xD;
               -  have a lung condition (such as cystic fibrosis, asthma, COPD, emphysema or&#xD;
                  bronchitis)&#xD;
&#xD;
               -  have heart disease (such as heart failure)&#xD;
&#xD;
               -  have high blood pressure (hypertension)&#xD;
&#xD;
               -  have diabetes&#xD;
&#xD;
               -  have chronic kidney disease&#xD;
&#xD;
               -  have liver disease (such as hepatitis)&#xD;
&#xD;
               -  have a condition affecting the brain or nerves (such as Parkinson's disease,&#xD;
                  motor neurone disease, multiple sclerosis, or cerebral palsy)&#xD;
&#xD;
               -  have a problem with the spleen or have had the spleen removed&#xD;
&#xD;
               -  have a condition with high risk of getting infections (such as SCID, sickle cell,&#xD;
                  HIV, lupus or scleroderma)&#xD;
&#xD;
               -  are taking medicine that can affect the immune system (such as steroids)&#xD;
&#xD;
               -  are very obese (a BMI of 40 or above)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David R Woods, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Royal Centre of Defence Medicine, Birmingham, UK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julie P Greeves, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Army Health and Performance Research, Andover, UK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Neil Walsh, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Liverpool John Moores University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David R Woods, MD</last_name>
    <phone>00441214158660</phone>
    <email>doctordrwoods@aol.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>John O'Hara, PhD</last_name>
    <phone>00441138125239</phone>
    <email>J.OHara@leedsbeckett.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Headingley and City campuses, Leeds Beckett University</name>
      <address>
        <city>Leeds</city>
        <state>Yorkshire</state>
        <zip>LS6 3QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John O'Hara, PhD</last_name>
      <phone>00441138125239</phone>
      <email>J.OHara@leedsbeckett.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Infantry Training Centre Catterick</name>
      <address>
        <city>Catterick Garrison</city>
        <zip>DL9 4HH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fiona Koivula, PhD</last_name>
      <phone>00447462817020</phone>
      <email>fiona.koivula928@mod.gov.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 16, 2020</study_first_submitted>
  <study_first_submitted_qc>July 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2020</study_first_posted>
  <last_update_submitted>March 19, 2021</last_update_submitted>
  <last_update_submitted_qc>March 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Cholecalciferol</keyword>
  <keyword>Vitamin D Status</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Acute Respiratory Tract Infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Anonymised IPD may be available upon request</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

